Evoke Pharma Inc (EVOK) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Evoke Pharma Inc (EVOK) has a cash flow conversion efficiency ratio of -0.155x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-521.96K) by net assets ($3.36 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Evoke Pharma Inc - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Evoke Pharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read how much debt does Evoke Pharma Inc carry for a breakdown of total debt and financial obligations.
Evoke Pharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Evoke Pharma Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Aelis Farma SA
PA:AELIS
|
-0.635x |
|
Mesiniaga Bhd
KLSE:5011
|
0.048x |
|
Hubei Geoway Investment Co Ltd
SHG:600462
|
0.893x |
|
Dev Information Technology Limited
NSE:DEVIT
|
0.054x |
|
4Sight Holdings Ltd
JSE:4SI
|
0.083x |
|
Konsolidator AS
CO:KONSOL
|
0.165x |
|
Korea Mcnulty Co Ltd
KQ:222980
|
0.126x |
|
edding AG
F:EDD3
|
0.003x |
Annual Cash Flow Conversion Efficiency for Evoke Pharma Inc (2011–2024)
The table below shows the annual cash flow conversion efficiency of Evoke Pharma Inc from 2011 to 2024. For the full company profile with market capitalisation and key ratios, see Evoke Pharma Inc (EVOK) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $7.04 Million | $-5.46 Million | -0.776x | -140.13% |
| 2023-12-31 | $-2.58 Million | $-4.98 Million | 1.933x | +219.67% |
| 2022-12-31 | $4.08 Million | $-6.60 Million | -1.615x | +53.53% |
| 2021-12-31 | $3.56 Million | $-12.35 Million | -3.475x | -268.47% |
| 2020-12-31 | $-3.21 Million | $-6.63 Million | 2.062x | +256.79% |
| 2019-12-31 | $4.38 Million | $-5.76 Million | -1.315x | +24.13% |
| 2018-12-31 | $4.03 Million | $-6.98 Million | -1.734x | +56.93% |
| 2017-12-31 | $2.17 Million | $-8.72 Million | -4.025x | -75.07% |
| 2016-12-31 | $3.79 Million | $-8.71 Million | -2.299x | +24.10% |
| 2015-12-31 | $3.46 Million | $-10.50 Million | -3.029x | -142.01% |
| 2014-12-31 | $9.19 Million | $-11.50 Million | -1.252x | -772.10% |
| 2013-12-31 | $21.18 Million | $-3.04 Million | -0.144x | -261.24% |
| 2012-12-31 | $-19.66 Million | $-1.75 Million | 0.089x | -45.68% |
| 2011-12-31 | $-17.65 Million | $-2.89 Million | 0.164x | -- |
About Evoke Pharma Inc
Evoke Pharma, Inc. operates as a specialty pharmaceutical company that focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medi… Read more